Profile

Douglas S. Hawkins, MD

Douglas S. Hawkins, MD

Hematology-Oncology

On staff since February 1996

Children's Title: Associate Division Chief, Hematology/Oncology

Academic Title: Professor of Pediatrics, UW School of Medicine

Research Center: Center for Clinical and Translational Research

"I feel exceptionally fortunate to work with some of the smartest people I know. Every day brings new opportunities to learn from my colleagues, patients and families. By the nature of our work in Hematology/Oncology, there is never a question about the importance of what we do every day. I am continually impressed that we have the opportunity to change the lives of children and young adults for the better, both with good clinical care and by leading clinical and translational research efforts. My hope is that the clinical research we do today will lead to more effective treatments with fewer side effects for children and young adults in the future."

Douglas S. Hawkins, MD, is Associate Hematology/Oncology Division Chief, Associate Director of the Center for Clinical and Translational Research at Seattle Childrens Hospital (SCH), clinician at SCH, and professor at the University of Washington School of Medicine. Hawkins is the principal investigator for COG activity at SCH and chair of the COG Soft Tissue Sarcoma Committee.

He is a steering committee member of several COG committees, including the Soft Tissue Sarcoma, Bone Tumor, and Voting Body. He is also the Chair of the COG Scientific and Discipline Chairs Committee. Dr. Hawkins has focused on clinical research, particularly in the treatment of pediatric sarcomas. He is the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma. He is collaborating on a pharmacogenomic study investigating cyclophosphamide metabolism and toxicity, both locally and as part of two COG studies. In addition, he collaborates on the use of FDG PET to assess response and guide treatment in pediatric sarcomas.

Recommendations

  • Kelly Seattle, WA 07.09.13

    Our sons life was saved by Dr. Hawkins and his incredible team. From the confusion and shock of the initial diagnosis to end of treatment celebration, Dr. Hawkins not only walked by our son's side every step of the way, he personally invested in our entire family. Dr. Hawkins is equal parts honest, courageous, brilliant, and compassionate. Dr. Hawkins and his team are an inspiration, and our family is eternally grateful for all that they do!

  • Rahil Kent, WA 10.19.12

    Dr. Hawkins is a professional, kind and caring doctor with a large expertise in treating childhood cancer. Upon our orientation at Children's, he was the key person that explained the medicines, treatment plan, schedule and expectations. He explained differences in treatment plans in Europe and North America. He presented our scans, biopsy and test results making sure that we understood everything. He has done a good job and our son is now cured of cancer. Thank you Dr. Hawkins and the expert staff at Seattle Children's!

  • Heather Snoqualmie, WA 09.25.12

    Dr. Hawkins and his incredible team saved out daughters life. Dr. Hawkins had the insight to look past the original diagnosis given to our daughter. She was diagnosed with TEC at 15 months with a HCT of 7. This was not life sustaining. He and his team consulted, worked, planned and communitcated with each other and our family to come up with the best course of treatment. I cant thank Dr. Hawkins and Seattle Children's enough. They preform miracles everyday!

  • janice wenatchee, wa. 02.13.12

    Dr. Hawkins works around the clock to give our children the best care. I am happy to say my son is a bone cancer survivor. I appreciated how Dr. Hawkins worked to make sure the side affects from the chemo where addressed as well as its progress. Thank you so much, Janice B.

  • elce kent,washinton 09.28.11

    Dr. Hawkins saved my daughters life,who was diagnosed with stage 4 alveolar rhabdomyosarcoma last year.My daughter is cancer free for almost three months now because of Dr. Hawkins and his team.God bless them.God is Good.

  • Becky seattle ,wa 06.16.11

    I was a distraught parent when my daughter was diagnosed at 15 with Hodgkin's lymphoma. he spent the time to make me feel at ease and encouraged me to participate in her care . i didn't have a clue what i should do . he made me feel comfortable to ask a lot of questions, and he answered with reassurance and calmness . He worked closely with me as a parent as well as his colleagues to give her the best care she could get. he responded as quickly as possible to all of my phone calls. He is a very humble man for all of his qualifications . there are a lot of people who look up to him , if he only knew how many .... many thanks!! we pray for his continued success!!

  • Lynora Ketchikan, Alaska 04.14.11

    Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!

  • Kathleen Seattle, WA 03.30.11

    If you are seeing Dr. Hawkins, you've likely heard the worst thing you will ever hear: your child has cancer. If that's the case, thank God you're seeing Dr. Hawkins! My son nearly died before he was diagnosed in 1997 at age 2 with Burkitt's Lymphoma. We were so grateful to have Dr. Hawkins on his team. He's honest, clear, compassionate and simply the most knowledgeable physician treating kids today. My son is 16 now, rowing crew and making the honor roll!

  • camille seattle washington 02.17.11

    Dr. Hawkins is my personal Hero! I was two weeks short of dying when he took over. I had stage 4 hodgkins lymphoma I was 15 yrs old. I am now 20 and I have a beautiful son and have been in remisson for 5 yrs now. Thank you Dr. Hawkins!

  • Lynora Ketchikan, Alaska 04.14.11

    Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!

  • Tammy Maple Valley, WA 12.10.10

    Dr. Doug Hawkins and Dr. Lawrence Cooper diagnosed our son Eric as a Lg Cell Lymphoma patient in early 1997 when he was 10. Eric recently had his 24th Birthday, THANKS TO THEIR KNOWLEDGE AND CARE. He is a SURVIVOR!! Thank you to them and all the wonderful nurses that made that hard time bearable. Sincerely, Eric's Mom & Dad

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

Harvard Medical School, Boston

Residency

Pediatrics, University of Washington, Seattle

Clinical Interests

Sarcomas, New therapy

Research Description

My clinical research is particularly focused in the treatment of pediatric sarcomas. I am the Children's Oncology Group (COG) chair of the Soft Tissue Sarcoma Committee, which designs and conducts all national studies in pediatric soft tissue sarcomas, including rhabdomyosarcoma. I am the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma, and the vice chair of three other COG clinical trials. I am working collaboratively on a pharmacogenomic study investigating cyclophospharmide metabolism and toxicity, both locally and as part of two COG studies, and on the use of FDG PET to assess response and guide treatment in pediatric sarcomas.

Research Focus Area

Cancer

Awards and Honors

Award Name Award Description Awarded By Award Date
SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
Seattle's Top Doc Seattle Met Magazine 2013
Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
U.S. News Top Doctor U.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
"Guide to America's Top Pediatricians" Consumer's Research Council of America 2009

Publications

  • Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM
    Myogenin, AP2, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    The American journal of surgical pathology , 2014 Mar. 10
  • Rosenberg AR, Anderson JR, Lyden E, Rodeberg DA, Wolden SL, Kao SC, Parham DM, Arndt C, Hawkins DS
    Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
    European journal of cancer (Oxford, England : 1990) , 2014 Mar. : 50(4)816-23
  • Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J
    Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
    Cancer discovery , 2014 Feb. : 4(2)216-31
  • Russell H, Swint JM, Lal L, Meza J, Walterhouse D, Hawkins DS, Okcu MF
    Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: A report from the Children's Oncology Group.
    Pediatric blood & cancer , 2014 Jan. 22
  • Eary JF, Conrad EU, O'Sullivan J, Hawkins DS, Schuetze SM, O'Sullivan F
    Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
    The Journal of bone and joint surgery. American volume , 2014 Jan. 15 : 96(2)152-8
  • Lupo PJ, Zhou R, Skapek SX, Hawkins DS, Spector LG, Scheurer ME, Fatih Okcu M, Melin B, Papworth K, Erhardt EB, Grufferman S
    Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group.
    International journal of cancer. Journal international du cancer , 2014 Jan. 15 : 134(2)431-6
  • Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA, St. Jude Childrens Research HospitalWashington University Pediatric Cancer Genome Project
    Targeting oxidative stress in embryonal rhabdomyosarcoma.
    Cancer cell , 2013 Dec. 9 : 24(6)710-24
  • Spalding AC, Hawkins DS, Donaldson SS, Anderson JR, Lyden E, Laurie F, Wolden SL, Arndt CA, Michalski JM
    The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.
    International journal of radiation oncology, biology, physics , 2013 Nov. 1 : 87(3)512-6
  • Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL
    A novel algorithm for simplification of complex gene classifiers in cancer.
    Cancer research , 2013 Sept. 15 : 73(18)5625-32
  • Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, Wolden SL, Parham DM, Rodeberg DA, Kao SC, Womer RB
    Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2013 Sept. 10 : 31(26)3226-32
  • Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS
    PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Pediatric blood & cancer , 2013 Sept. : 60(9)1411-7
  • Lupo PJ, Zhou R, Skapek SX, Hawkins DS, Spector LG, Scheurer ME, Fatih Okcu M, Melin B, Papworth K, Erhardt EB, Grufferman S
    Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: A report from the children's oncology group.
    International journal of cancer. Journal international du cancer , 2013 July 3
  • Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, Raney RB
    Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.
    Pediatric blood & cancer , 2013 July : 60(7)1108-12
  • Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM
    Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    American journal of clinical pathology , 2013 July : 140(1)82-90
  • Newman EN, Jones RL, Hawkins DS
    An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
    Pediatric blood & cancer , 2013 July : 60(7)1113-7
  • Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, Raney RB
    Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.
    Pediatric blood & cancer , 2013 July : 60(7)1108-12
  • Hawkins DS, Spunt SL, Skapek SX, COG Soft Tissue Sarcoma Committee
    Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.
    Pediatric blood & cancer , 2013 June : 60(6)1001-8
  • Raney B, Huh W, Hawkins D, Hayes-Jordan A, Million L, Rodeberg D, Teot L, Anderson J, Soft Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, CA
    Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
    Pediatric blood & cancer , 2013 Mar. : 60(3)371-6
  • Gardner RA, Thomson B, Hawkins DS
    Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
    Pediatric blood & cancer , 2013 Feb. : 60(2)338-9
  • MacQuarrie KL, Yao Z, Fong AP, Diede SJ, Rudzinski ER, Hawkins DS, Tapscott SJ
    Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors.
    Molecular and cellular biology , 2013 Feb. : 33(4)773-84
  • Soundararajan A, Abraham J, Nelon LD, Prajapati SI, Zarzabal LA, Michalek JE, McHardy SF, Hawkins DS, Malempati S, Keller C
    18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.
    Pediatric blood & cancer , 2012 Sept. : 59(3)485-92
  • Malempati S, Hawkins DS
    Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
    Pediatric blood & cancer , 2012 July 15 : 59(1)5-10
  • Rosenberg AR, Skapek SX, Hawkins DS
    The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology , 2012 July : 21(7)1012-8
  • Spunt SL, Vargas SO, Coffin CM, Skapek SX, Parham DM, Darling J, Hawkins DS, Keller C
    The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Cancer , 2012 June 15 : 118(12)3002-9
  • Breneman J, Meza J, Donaldson SS, Raney RB, Wolden S, Michalski J, Laurie F, Rodeberg DA, Meyer W, Walterhouse D, Hawkins DS
    Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
    International journal of radiation oncology, biology, physics , 2012 June 1 : 83(2)720-6
  • Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS
    Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Cancer , 2012 Feb. 15 : 118(4)1130-7
  • Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA
    Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
    Drug metabolism and disposition: the biological fate of chemicals , 2012 Jan. : 40(1)54-63
  • Hingorani P, Seidel K, Krailo M, Mascarenhas L, Meyers P, Marina N, Conrad EU, Hawkins DS
    Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group.
    Pediatric blood & cancer , 2011 Dec. 1 : 57(6)939-42
  • Stephenson J, Gow KW, Meehan J, Hawkins DS, Avansino J
    Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent.
    Pediatric blood & cancer , 2011 Oct. : 57(4)691-2
  • Hawkins DS
    Sarcomas gone bad: what to do about recurrent Ewing sarcoma.
    Pediatric blood & cancer , 2011 Oct. : 57(4)535-6
  • Malempati S, Rodeberg DA, Donaldson SS, Lyden ER, Anderson JR, Hawkins DS, Arndt CA
    Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.
    Cancer , 2011 Aug. 1 : 117(15)3493-501
  • Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, Arndt C, Raney RB, Meyer WH, Hawkins DS
    Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
    Pediatric blood & cancer , 2011 July 15 : 57(1)76-83
  • Foster JH, Hawkins DS, Loken MR, Wells DA, Thomson B
    Minimal residual disease detected prior to hematopoietic cell transplantation.
    Pediatric blood & cancer , 2011 July 15 : 57(1)163-5
  • La TH, Wolden SL, Rodeberg DA, Hawkins DS, Brown KL, Anderson JR, Donaldson SS
    Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.
    International journal of radiation oncology, biology, physics , 2011 July 15 : 80(4)1151-7
  • Million L, Anderson J, Breneman J, Hawkins DS, Laurie F, Michalski J, Rodeberg D, Wharam M, Wolden S, Donaldson SS, Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group.
    International journal of radiation oncology, biology, physics , 2011 June 1 : 80(2)333-8
  • Rodeberg DA, Stoner JA, Garcia-Henriquez N, Randall RL, Spunt SL, Arndt CA, Kao S, Paidas CN, Million L, Hawkins DS
    Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Cancer , 2011 June 1 : 117(11)2541-50
  • La TH, Wolden SL, Su Z, Linardic C, Randall RL, Hawkins DS, Donaldson SS
    Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.
    International journal of radiation oncology, biology, physics , 2011 May 1 : 80(1)206-12
  • Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS
    Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Apr, 1 : 29(10)1304-11
  • Eary JF, Hawkins DS, Rodler ET, Conrad EU 3rd
    (18)F-FDG PET in sarcoma treatment response imaging.
    American journal of nuclear medicine and molecular imaging , 2011 : 1(1)47-53
  • Rodeberg DA, Stoner JA, Garcia-Henriquez N, Randall RL, Spunt SL, Arndt CA, Kao S, Paidas CN, Million L, Hawkins DS
    Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the children's oncology group.
    Cancer , 2010 Dec. 14
  • Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS
    Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Oct. 20 : 28(30)4658-63
  • Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ
    Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Oct. 10 : 28(29)e587-8; author reply e589-90
  • Minn AY, Lyden ER, Anderson JR, Million L, Arndt CA, Brown K, Hawkins DS, Donaldson SS
    Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Sept. 20 : 28(27)4228-32
  • Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES
    Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2010 Aug. 1 : 16(15)4024-30
  • Koschmann C, Thomson B, Hawkins DS
    No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
    Archives of pediatrics & adolescent medicine , 2010 Mar. : 214-7
  • Schmale GA, Hawkins DS, Rutledge J, Conrad EU
    Malignant progression in two children with multiple osteochondromas.
    Sarcoma , 2010 : 2010417105
  • Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM
    Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2009 Dec. 1 : 15(23)7361-7
  • Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH
    Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Nov. 1 : 27(31)5182-8
  • Borinstein SC, Pollard J, Winter L, Hawkins DS
    Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors.
    Pediatric blood & cancer , 2009 Sept. : 53(3)375-8
  • Rodeberg DA, Stoner JA, Hayes-Jordan A, Kao SC, Wolden SL, Qualman SJ, Meyer WH, Hawkins DS
    Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Aug. 1 : 27(22)3705-11
  • Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF
    [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
    Cancer , 2009 Aug. 1 : 115(15)3519-25
  • Rodeberg DA, Stoner JA, Hayes-Jordan A, Kao SC, Wolden SL, Qualman SJ, Meyer WH, Hawkins DS
    Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Aug. 1 : 3705-11
  • Imran H, Enders F, Krailo M, Sim F, Okuno S, Hawkins D, Neglia J, Randall RL, Womer R, Mascarenhas L, Arndt CA
    Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.
    The Journal of bone and joint surgery. American volume , 2009 Mar. 1 : 91(3)604-12
  • Cengiz P, Zemlan F, Ellenbogen R, Hawkins D, Zimmerman JJ
    Cerebrospinal fluid cleaved-tau protein and 9-hydroxyoctadecadienoic acid concentrations in pediatric patients with hydrocephalus.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies , 2008 Sept. : 9(5)524-9
  • Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF, Kleinerman ES
    COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
    Journal of pediatric hematology/oncology , 2008 July : 30(7)507-12
  • Wirojanan J, Kraff J, Hawkins DS, Laird C, Gane LW, Angkustsiri K, Tassone F, Hagerman RJ
    Two boys with fragile x syndrome and hepatic tumors.
    Journal of pediatric hematology/oncology , 2008 Mar. : 30(3)239-41
  • Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR
    Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Pediatric blood & cancer , 2008 Jan. : 50(1)33-6
  • Borinstein SC, Xu M, Hawkins DS
    Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
    Pediatric blood & cancer , 2008 Jan. : 50(1)189
  • Douglas JG, Arndt CA, Hawkins DS
    Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
    European journal of cancer (Oxford, England : 1990) , 2007 Apr, : 43(6)1045-50
  • Greene S, Hawkins DS, Rutledge JC, Tsuchiya KD, Douglas J, Ellenbogen RG, Avellino AM
    Pediatric intradural extramedullary synovial sarcoma: case report.
    Neurosurgery , 2006 Dec. : E1339; discussion E1339
  • Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G
    Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Pediatric blood & cancer , 2006 Nov. : 47(6)790-4
  • Taylor JA, Winter L, Geyer LJ, Hawkins DS
    Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
    Cancer , 2006 Sept. 15 : 107(6)1400-6
  • Morgan HD, Cizik AM, Leopold SS, Hawkins DS, Conrad EU 3rd
    Survival of tumor megaprostheses replacements about the knee.
    Clinical orthopaedics and related research , 2006 Sept. : 45039-45
  • Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU 3rd, Eary JF
    [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Dec. 1 : 23(34)8828-34
  • Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA
    Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2005 Nov. 15 : 11(22)8089-96
  • Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES
    Fas expression in lung metastasis from osteosarcoma patients.
    Journal of pediatric hematology/oncology , 2005 Nov. : 27(11)611-5
  • Spiller SE, Hawkins DS, Finn LS, Sze RW, Sybert V
    Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy.
    Pediatric blood & cancer , 2005 July : 45(1)60-3
  • Barker LM, Pendergrass TW, Sanders JE, Hawkins DS
    Survival after recurrence of Ewing's sarcoma family of tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 July 1 : 23(19)4354-62
  • Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF
    Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Cancer , 2005 Jan. 15 : 103(2)339-48
  • Hawkins DS
    Transatlantic collaboration in pediatric oncology: now is the time.
    Journal of pediatric hematology/oncology , 2004 Dec. : 26(12)783-4
  • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS
    Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
    Pediatric blood & cancer , 2004 Oct. : 571-9
  • Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI
    Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2004 Aug. 15 : 5335-41
  • McCune JS, Friedman DL, Schuetze S, Blough D, Magbulos M, Hawkins DS
    Influence of age upon Ifosfamide-induced nephrotoxicity.
    Pediatric blood & cancer , 2004 May : 42(5)427-32
  • Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR
    Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
    Cancer , 2004 Mar. 15 : 100(6)1268-75
  • Finn LS, Hawkins DS, Rutledge JC, Patterson K
    Evaluation of early marrow response in childhood aneuploid acute lymphoblastic leukemia: flow cytometric DNA analysis versus standard morphology.
    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society , 2004 Jan. : 7(1)39-47
  • Hawkins DS, Arndt CA
    Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
    Cancer , 2003 Dec. 1 : 98(11)2447-56
  • Smith SC, Lindsley SK, Felgenhauer J, Hawkins DS, Douglas JG
    Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
    Journal of pediatric hematology/oncology , 2003 Oct. : 25(10)774-9
  • Wright JA, Bradfield SM, Park JR, Hawkins DS
    Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
    Journal of pediatric hematology/oncology , 2003 Apr, : 25(4)286-91
  • Wright JA, Bradfield SM, Park JR, Hawkins DS
    Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
    Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Apr, : 286-91
  • Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T
    Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Medical and pediatric oncology , 2003 Feb. : 40(2)93-8
  • Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW
    Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Cancer , 2002 Sept. 15 : 1354-65
  • Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ
    Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
    Journal of pediatric hematology/oncology , 2002 Aug. : 24(6)440-6
  • Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF
    Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Cancer , 2002 June 15 : 94(12)3277-84

Presentations

Presentations Title Event Location Date
Progress in the treatment of rhabdomyosarcoma: results of the North American strategy European Cancer Congress Amsterdam, Netherlands Sept. 29, 2013
Childrens Oncology Group update on soft tissue sarcoma clinical trials European Paediatric Soft Tissue Sarcoma Meeting Paris, France March 22, 2013
COG approach to identification and introduction of new/targeted therapies in RMS/STS European Paediatric Soft Tissue Sarcoma Meeting Paris, France, March 22, 2013
Rhabdomyosarcoma: How many and how to treat Texas Childrens Cancer Center Houston, TX Feb. 14, 2013
What children have taught me about rhabdomyosarcoma Pediatric Grand Rounds, Childrens Hospital at Montefiore Bronx, NY Jan. 30, 2013
From Seattle to Sydney: lessons from selected pediatric sarcoma cases Pediatric Oncology Conference Sydney, Australia Oct. 8, 2012
Childrens Oncology Group update on soft tissue sarcoma clinical trials International Symposium on the Biology and Treatment of the Pediatric Soft Tissue Sarcomas Padova, Italy Dec. 6, 2011
Risk stratification and treatment approaches in rhabdomyosarcoma: a comparison of Europe and North America Pediatric Oncology Group of Ontario Nov. 19, 2010

Research Funding

Grant Title Grantor Amount Award Date
Pharmacogenetics of Cyclophosphamide ADRs in Children NIH/NCI $38,844 Sept. 1, 2011 - Aug. 31, 2013
Molecular Targeting in Non-Rhabdomyosarcoma Soft Tissue Sarcoma St. Baldricks Foundation $11,380 Sept. 1, 2011 - Aug. 31, 1914
Early Phase Trials and Biologic Specimen Collection at Seattle Childrens Hospital Rally Foundation $88,170 July 1, 2011 - June 30, 2012
Children’s Oncology Group trial AEWS0531 NIH $11,956.00 March 1, 2009
Children’s Oncology Group trial AEWS0331 NIH $11,956.00 March 1, 2009
Children’s Oncology Group Soft Tissue Sarcoma Committee Chair NIH $23.913.00 March 1, 2009
Children’s Oncology Group- cooperative group trial, Institutional Principal NIH $57,390.00 March 1, 2009